Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.48 |
| ▸ | GBA1 | P04062 | 6/20 | 0.47 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10299507 | 0.95 | HRH4 (0.54) | HRH4HRH3CYP19A1GBA1GGPS1 | |
| SCHEMBL18757279 | 0.94 | CYP19A1 (0.56) | HRH4HRH3CYP19A1GBA1GGPS1 | |
| SCHEMBL10079147 | 0.94 | CYP19A1 (0.56) | HRH4HRH3CYP19A1GBA1GGPS1 | |
| SCHEMBL19224588 | 0.94 | CYP19A1 (0.56) | HRH4HRH3CYP19A1GBA1GGPS1 | |
| SCHEMBL9926315 | 0.92 | HRH4 (0.51) | HRH4HRH3L3MBTL1CYP19A1GBA1 | |
| SCHEMBL18391502 | 0.91 | GBA1 (0.51) | HRH4HRH3L3MBTL1CYP19A1GBA1 | |
| SCHEMBL3434876 | 0.90 | HRH4 (0.42) | HRH4HRH3L3MBTL1CYP19A1GBA1 | |
| SCHEMBL3533937 | 0.90 | CYP19A1 (0.51) | HRH4HRH3L3MBTL1CYP19A1GBA1 | |
| SCHEMBL23918008 | 0.89 | GBA1 (0.53) | HRH4HRH3L3MBTL1CYP19A1GBA1 | |
| SCHEMBL21671071 | 0.89 | GBA1 (0.53) | HRH4HRH3L3MBTL1CYP19A1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-10772934-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200231638-A1 | STABILIZED ANTI-MICROBIAL PEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. | 2020-07-23 | — | — | US | disclosed |
| US-10543255-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190071469-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2019-03-07 | — | — | US | disclosed |
| US-10030049-B2 | Triazole macrocycle systems | AILERON THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180193423-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180193422-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9957296-B2 | Triazole macrocycle systems | AILERON THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170037105-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20120178700-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | AILERON THERAPEUTICS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193423-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | HRH4 1253/4885HRH3 1725/4885L3MBTL1 876/4885 |
| US-20180193422-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | HRH4 1644/4885HRH3 2078/4885L3MBTL1 1086/4885 |
| US-10030049-B2 | Triazole macrocycle systems | FLT3, VIP, NGLY1 | HRH4 1806/4885HRH3 1158/4885L3MBTL1 1750/4885 |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | BID, FLT3, GRPR | HRH4 2639/4885HRH3 2900/4885L3MBTL1 1206/4885 |
| US-20190071469-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | PCNA, MKI67, NFATC1 | HRH4 3022/4885HRH3 2281/4885L3MBTL1 1005/4885 |
| US-20170037105-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | HRH4 1954/4885HRH3 2166/4885L3MBTL1 1262/4885 |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | VIP, ANPEP, DNPEP | HRH4 4460/4885HRH3 3972/4885L3MBTL1 1368/4885 |
| US-10772934-B2 | Highly active polypeptides and methods of making and using the same | SCTR, GIPR, APLNR | HRH4 1644/4885HRH3 2078/4885L3MBTL1 1086/4885 |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | HRH4 4550/4885HRH3 4280/4885L3MBTL1 2240/4885 |
| US-10543255-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | APLNR, SCTR, GIPR | HRH4 1253/4885HRH3 1725/4885L3MBTL1 876/4885 |
| US-20120178700-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | HRH4 1851/4885HRH3 2016/4885L3MBTL1 709/4885 |
| US-20200231638-A1 | STABILIZED ANTI-MICROBIAL PEPTIDES | VIP, CTSA, HM13 | HRH4 1709/4885HRH3 1881/4885L3MBTL1 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.